|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Minerva Neurosciences, Inc.
| | | Phone: | (617) 600-7373 | Year Established: | 2007 | Ticker: | NERV | Exchange: | NASDAQ | Main Contact: | Remy Luthringer, Ph.D., CEO | | Other Contacts: | Jay B. Saoud, Senior VP, Head, R&D Devin Smith, Senior VP & General Counsel Joseph Reilly, Senior VP & COO Fred Ahlholm, Senior VP & Chief Accounting Officer Geoff Race, FCMA, MBA, Executive VP, CFO & CBO Michael Davidson, M.D., CMO Richard Russell, President Justine Lalonde, M.D., MBA, Senior VP, Product Strategy
| | Company Description | Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in development for the treatment of schizophrenia; MIN-202 (JNJ-42847922), in development for the treatment of insomnia; MIN-117, in development for the treatment of major depressive disorder; and MIN-301, in development for the treatment of Parkinson's disease. | |
|
|
|
|
|